Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 296-306

  Chang, Pishan ^a   Walker, Matthew C ^b   Williams, Robin S B ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Kainic acid; MTOR2; Pentylenetetrazol; PKB AKT; Seizure control; Valproic acid (VPA)

Indexed keywords

AMPA RECEPTOR; KAINIC ACID; NEOMYCIN; PENTETRAZOLE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN KINASE B; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; ENTORHINAL CORTEX; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; LIPID BRAIN LEVEL; MALE; NONHUMAN; POSITIVE FEEDBACK; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; RAT; SEIZURE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WESTERN BLOTTING;

KAINIC ACID; MTOR2; PENTYLENETETRAZOL; PIP(3); PKB/AKT; SEIZURE CONTROL; VALPROIC ACID (VPA);

ANIMALS; ANTICONVULSANTS; CELLS, CULTURED; GABA ANTAGONISTS; HIPPOCAMPUS; KAINIC ACID; MALE; NEURONS; PENTYLENETETRAZOLE; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; STATUS EPILEPTICUS; VALPROIC ACID;

EID: 84887187281     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.10.017     Document Type: Article

References (76)

1. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 1997, 7:261-269.
2. Andrews S., Stephens L.R., Hawkins P.T. PI3K class IB pathway. Sci. STKE 2007, 2007:cm2.
3. Apsel B., Blair J.A., Gonzalez B., Nazif T.M., Feldman M.E., Aizenstein B., Hoffman R., Williams R.L., Shokat K.M., Knight Z.A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 2008, 4:691-699.
4. Arendt K.L., Royo M., Fernandez-Monreal M., Knafo S., Petrok C.N., Martens J.R., Esteban J.A. PIP3 controls synaptic function by maintaining AMPA receptor clustering at the postsynaptic membrane. Nat. Neurosci. 2010, 13:36-44.
5. 2+ in rat entorhinal cortex-hippocampus slices. Epilepsy Res. 1998, 32:345-355.
6. Backman S.A., Stambolic V., Suzuki A., Haight J., Elia A., Pretorius J., Tsao M.S., Shannon P., Bolon B., Ivy G.O., Mak T.W. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 2001, 29:396-403.
7. Balding F., Geller H.M. Sodium valproate enhancement of gamma-aminobutyric acid (GABA) inhibition: electrophysiological evidence for anticonvulsant activity. J. Pharmacol. Exp. Ther. 1981, 217:445-450.
8. Baraban S.C., Taylor M.R., Castro P.A., Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 2005, 131:759-768.
9. Bates R.C., Stith B.J., Stevens K.E. Chronic central administration of valproic acid: increased pro-survival phospho-proteins and growth cone associated proteins with no behavioral pathology. Pharmacol. Biochem. Behav. 2012, 103:237-244.
10. Bechard M., Trost R., Singh A.M., Dalton S. Frat is a phosphatidylinositol 3-kinase/Akt-regulated determinant of glycogen synthase kinase 3beta subcellular localization in pluripotent cells. Mol. Cell. Biol. 2012, 32:288-296.
11. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989, 59:411-419.
12. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 2010, 9:68-82.
13. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 2010, 92:89-124.
14. Boeckeler K., Adley K., Xu X., Jenkins A., Jin T., Williams R.S. The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum. Eur. J. Cell Biol. 2006, 85:1047-1057.
15. Bolanos A.R., Sarkisian M., Yang Y., Hori A., Helmers S.L., Mikati M., Tandon P., Stafstrom C.E., Holmes G.L. Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology 1998, 51:41-48.
16. Brandt C., Gastens A.M., Sun M., Hausknecht M., Loscher W. Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 2006, 51:789-804.
17. Buckmaster P.S., Lew F.H. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J. Neurosci. 2011, 31:2337-2347.
18. Buckmaster P.S., Ingram E.A., Wen X. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci. 2009, 29:8259-8269.
19. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
20. Chang P., Walker M.C. Valproate decreases frequency facilitation at mossy fiber-CA3 synapses after status epilepticus. Epilepsy Res. 2011, 93:192-196.
21. Chang P., Chandler K.E., Williams R.S., Walker M.C. Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP. Epilepsia 2010, 51:1533-1542.
22. Chang P., Orabi B., Deranieh R.M., Dham M., Hoeller O., Shimshoni J.A., Yagen B., Bialer M., Greenberg M.L., Walker M.C., Williams R.S. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis. Model Mech. 2012, 5:115-124.
23. Chang P., Terbach N., Plant N., Chen P.E., Walker M.C., Williams R.S. Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 2013, 69:105-114.
24. Davis G.W. Homeostatic control of neural activity: from phenomenology to molecular design. Annu. Rev. Neurosci. 2006, 29:307-323.
25. Di P.G., De C.P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006, 443:651-657.
26. Dyson J.M., Kong A.M., Wiradjaja F., Astle M.V., Gurung R., Mitchell C.A. The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2. Int. J. Biochem. Cell Biol. 2005, 37:2260-2265.
27. Eickholt B.J., Towers G., Ryves W.J., Eikel D., Adley K., Ylinen L., Chadborn N., Harwood A., Nau H., Williams R.S. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, GSK-3β inhibition and viral replication - a screening approach for new bipolar disorder drugs based on the valproic acid core structure. Mol. Pharmacol. 2005, 67:1-8.
28. Elphick L.M., Pawolleck N., Guschina I.A., Chaieb L., Eikel D., Nau H., Harwood J.L., Plant N.J., Williams R.S. Conserved valproic acid-induced lipid droplet formation in Dictyostelium and human hepatocytes (huh7) identifies structurally active compounds. Dis. Model Mech. 2011, 5:231-240.
29. Gabev E., Kasianowicz J., Abbott T., McLaughlin S. Binding of neomycin to phosphatidylinositol 4,5-bisphosphate (PIP2). Biochim. Biophys. Acta 1989, 979:105-112.
30. Galvan C.D., Hrachovy R.A., Smith K.L., Swann J.W. Blockade of neuronal activity during hippocampal development produces a chronic focal epilepsy in the rat. J. Neurosci. 2000, 20:2904-2916.
31. Godukhin O., Savin A., Kalemenev S., Levin S. Neuronal hyperexcitability induced by repeated brief episodes of hypoxia in rat hippocampal slices: involvement of ionotropic glutamate receptors and L-type Ca(2+) channels. Neuropharmacology 2002, 42:459-466.
32. Gupta Y.K., Briyal S., Chaudhary G. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol. Biochem. Behav. 2002, 71:245-249.
33. Haughey N.J., Holden C.P., Nath A., Geiger J.D. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J. Neurochem. 1999, 73:1363-1374.
34. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Okada M., Ohta M., Tsukamoto S., Parker P., Workman P., Waterfield M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 2006, 14:6847-6858.
35. Heinemann U., Draguhn A., Ficker E., Stabel J., Zhang C.L. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia 1994, 35(Suppl. 5):S10-S21.
36. Honore T., Davies S.N., Drejer J., Fletcher E.J., Jacobsen P., Lodge D., Nielsen F.E. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 1988, 241:701-703.
37. Huang R.Q., Bell-Horner C.L., Dibas M.I., Covey D.F., Drewe J.A., Dillon G.H. Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action. J. Pharmacol. Exp. Ther. 2001, 298:986-995.
38. Huang B.X., Akbar M., Kevala K., Kim H.Y. Phosphatidylserine is a critical modulator for Akt activation. J. Cell Biol. 2011, 192:979-992.
39. Kanzaki M., Zhang Y.Q., Mashima H., Li L., Shibata H., Kojima I. Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat. Cell Biol. 1999, 1:165-170.
40. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert. Rev. Neurother. 2006, 6:397-406.
41. Lagace D.C., O'Brien W.T., Gurvich N., Nachtigal M.W., Klein P.S. Valproic acid: how it works. Or not. Clin. Neurosci. Res. 2005, 4:215-225.
42. Lamarre M., Desrosiers R.R. Up-regulation of protein l-isoaspartyl methyltransferase expression by lithium is mediated by glycogen synthase kinase-3 inactivation and beta-catenin stabilization. Neuropharmacology 2008, 55:669-676.
43. Lee C.C., Huang C.C., Wu M.Y., Hsu K.S. Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J. Biol. Chem. 2005, 280:18543-18550.
44. Lhuillier L., Dryer S.E. Developmental regulation of neuronal K(Ca) channels by TGFbeta1: an essential role for PI3 kinase signaling and membrane insertion. J. Neurophysiol. 2002, 88:954-964.
45. Li R., El Mallahk R.S. A novel evidence of different mechanisms of lithium and valproate neuroprotective action on human SY5Y neuroblastoma cells: caspase-3 dependency. Neurosci. Lett. 2000, 294:147-150.
46. Ljungberg M.C., Sunnen C.N., Lugo J.N., Anderson A.E., D'Arcangelo G. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis. Model Mech. 2009, 2:389-398.
47. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 1999, 58:31-59.
48. MacGregor G.G., Dong K., Vanoye C.G., Tang L., Giebisch G., Hebert S.C. Nucleotides and phospholipids compete for binding to the C terminus of KATP channels. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2726-2731.
49. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M., Kwiatkowski D.J. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 2008, 28:5422-5432.
50. Mora A., Gonzalez-Polo R.A., Fuentes J.M., Soler G., Centeno F. Different mechanisms of protection against apoptosis by valproate and Li+. Eur. J. Biochem. 1999, 266:886-891.
51. Nadler J.V. Minireview. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci. 1981, 29:2031-2042.
52. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982, 247:184-187.
53. Racine R.J., Gartner J.G., Burnham W.M. Epileptiform activity and neural plasticity in limbic structures. Brain Res. 1972, 47:262-268.
54. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
55. Schmid S.L. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu. Rev. Biochem. 1997, 66:511-548.
56. Shaltiel G., Mark S., Kofman O., Belmaker R.H., Agam G. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol. Rep. 2007, 59:402-407.
57. Shinoda S., Schindler C.K., Meller R., So N.K., Araki T., Yamamoto A., Lan J.Q., Taki W., Simon R.P., Henshall D.C. Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy. J. Clin. Invest. 2004, 113:1059-1068.
58. Spiliotis E.T., Nelson W.J. Spatial control of exocytosis. Curr. Opin. Cell Biol. 2003, 15:430-437.
59. Stokoe D., Stephens L.R., Copeland T., Gaffney P.R., Reese C.B., Painter G.F., Holmes A.B., McCormick F., Hawkins P.T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277:567-570.
60. Stone T.W., Burton N.R. NMDA receptors and ligands in the vertebrate CNS. Prog. Neurobiol. 1988, 30:333-368.
61. Sugaya E., Sugaya A., Takagi T., Tsuda T., Kajiwara K., Yasuda K., Komatsubara J. Pentylenetetrazole-induced changes of the single potassium channel in primary cultured cerebral cortical neurons. Brain Res. 1989, 497:239-244.
62. Suwa A., Yamamoto T., Sawada A., Minoura K., Hosogai N., Tahara A., Kurama T., Shimokawa T., Aramori I. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Br. J. Pharmacol. 2009, 158:879-887.
63. Terbach N., Williams R.S. Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 2009, 37:1126-1132.
64. Vaden D.L., Ding D., Peterson B., Greenberg M.L. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J. Biol. Chem. 2001, 276:15466-15471.
65. Vanhaesebroeck B., Stephens L., Hawkins P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 2012, 13:195-203.
66. Viard P., Butcher A.J., Halet G., Davies A., Nurnberg B., Heblich F., Dolphin A.C. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat. Neurosci. 2004, 7:939-946.
67. Wang G., Gilbert J., Man H.Y. AMPA receptor trafficking in homeostatic synaptic plasticity: functional molecules and signaling cascades. Neural Plast. 2012, 2012:825364.
68. Watkins J.C., Krogsgaard-Larsen P., Honore T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. 1990, 11:25-33.
69. Wilot L.C., Bernardi A., Frozza R.L., Marques A.L., Cimarosti H., Salbego C., Rocha E., Battastini A.M. Lithium and valproate protect hippocampal slices against ATP-induced cell death. Neurochem. Res. 2007, 32:1539-1546.
70. Workman P., Clarke P.A., Raynaud F.I., van Montfort R.L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010, 70:2146-2157.
71. Wu P., Hu Y.Z. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr. Med. Chem. 2010, 17:4326-4341.
72. Wu J.B., Shih J.C. Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. Mol. Pharmacol. 2011, 80:714-723.
73. Xu X., Muller-Taubenberger A., Adley K.E., Pawolleck N., Lee V.W., Wiedemann C., Sihra T.S., Maniak M., Jin T., Williams R.S. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot. Cell 2007, 6:899-906.
74. Zeng L.H., Rensing N.R., Wong M. Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mTOR) pathway. Mol. Cell. Pharmacol. 2009, 1:124-129.
75. Zeng L.H., McDaniel S., Rensing N.R., Wong M. Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword?. Cell Cycle 2010, 9:2281-2285.
76. Zhang B., Wong M. Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat. Epilepsia 2012, 53:506-511.